Inclusion Criteria:

1. Patients must have histologically or cytologically confirmed NSCLC

2. At least one or 2 prior lines of chemotherapy, including oral EGFR tyrosine-kinase
inhibitor for metastatic disease or locally advanced unresectable disease. There
should be at least 4 weeks since prior chemotherapy or radiation therapy; patients
who decline conventional chemotherapy or oral EGFR tyrosine-kinase inhibitor as
salvage 2nd or 3rd line treatment are also eligible.

3. Minimum body-surface area (BSA) of 1.4 m2 at point of recruitment. This is a
safeguard against recruiting small-built patients who may experience adverse reaction
on absolute dosing of oral vinorelbine. At this body surface area, the maximum
dosing of oral vinorelbine at 120 mg/week is equivalent to 86 mg/m2/week for a
patient with BSA of 1.4 m2.

4. Age >21 years

5. ECOG performance status <2 (Karnofsky >60%)

6. Patients must have normal organ and marrow function as defined here: leukocytes
>3,000/mcL, absolute neutrophil count >1,500/mcL, platelet count > 100,000/mcL, serum
bilirubin within normal institutional limits, AST(SGOT)/ALT(SGPT) <2.5 X upper limit
of normal, and creatinine within normal institutional limits or creatinine clearance
>60 mL/min/1.73 m2 for patients. These tests must be done within 1 week of study
treatment.

7. Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

1. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering
the study or those who have not recovered from adverse events due to agents
administered more than 4 weeks earlier

2. Patients receiving any other investigational agents

3. Patients with known brain metastases should be excluded from this clinical trial
because of their poor prognosis and because they often develop progressive neurologic
dysfunction that would confound the evaluation of neurologic and other adverse events

4. History of allergic reactions attributed to compounds of similar chemical or biologic
composition to Oral Vinorelbine or other agents used in study

5. Prior and / or concomitant treatment with drugs known to induce or inhibit cytochrome
P450 3A4: phenytoin, carbamazepine, barbiturates, rifampicin, imidazole antifungals
(such as ketoconazole, fluconazole, itraconazole, metronidazole), omeprazole and
ritonavir. Patients who are taking gastric acid-lowering agents such as H2
antagonist or antacids will be evaluated regarding the need to continue with these
medications. If discontinuation of these medications is medically contraindicated,
the patient will be excluded as these agents are known to lower the solubility of
sorafenib and hence may limit their efficacy.

6. Significant malabsorption syndrome or disease affecting the gastro-intestinal tract
function

7. Significant peripheral or autonomic neuropathy affecting sensation or bowel motility

8. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

9. Uncontrolled hypertension defined as systolic blood pressure >150 mmHg or diastolic
pressure >90 mmHg despite optimal management

10. Pregnancy or breast-feeding or women of childbearing potential not using effective
contraception

11. Evidence or history of bleeding diathesis or coagulopathy

12. Thrombotic or embolic events such as cerebrovascular accident including transient
ischemic attacks within the past 6 months

13. Pulmonary hemorrhage/bleeding event >CTCAE grade 2 within 4 weeks of recruitment

14. Any other hemorrhage/bleeding event >CTCAE grade 3 within 4 weeks of recruitment